Is Gout Genetic? What DNA Reveals About Uric Acid and Joint Pain

Gout has been misunderstood for centuries. Long dismissed as the consequence of overindulgence in rich food and alcohol, it carries a stigma that discourages many people from seeking proper care. The reality is far more nuanced. Modern genetics has revealed that serum uric acid levels, the central driver of gout, are approximately 65% heritable (Köttgen et al., 2013). Your DNA has more influence on whether you develop gout than your dinner plate does.

That does not mean diet is irrelevant. But it does explain a frustrating paradox: why one person can drink beer regularly without consequence while another develops agonizing joint flares after a single serving. The answer lies in the molecular machinery that moves uric acid through your kidneys and gut.

How Uric Acid Becomes a Problem

Uric acid is the final breakdown product of purines, molecules found in every cell and in many foods. Most mammals possess an enzyme called uricase that breaks uric acid down further, but humans lost this enzyme millions of years ago through a genetic mutation (Oda et al., 2002). As a result, we maintain blood uric acid levels roughly ten times higher than most other mammals.

When uric acid concentrations exceed the saturation threshold of approximately 6.8 mg/dL, monosodium urate (MSU) crystals can form and deposit in joints and soft tissues. The innate immune system recognizes these crystals as danger signals, activating the NLRP3 inflammasome and triggering the intense inflammatory cascade that defines a gout flare (Martinon et al., 2006). The big toe is the classic location, but gout can strike ankles, knees, wrists, and fingers as well.

Critically, the kidneys handle about 70% of uric acid excretion, with the gut managing the remaining 30% (Sorensen, 1965). Genetic variants that impair either pathway can push uric acid levels upward, sometimes dramatically.

The Key Genes Behind Gout Risk

SLC2A9 (GLUT9)

SLC2A9 encodes the GLUT9 transporter, the single most influential genetic determinant of serum uric acid levels. This transporter reabsorbs uric acid in the proximal tubule of the kidney. Key facts about SLC2A9:

• Largest effect size: Common variants in SLC2A9 can shift uric acid levels by as much as 0.5 mg/dL, a clinically meaningful amount (Vitart et al., 2008)
• GWAS signal: It is consistently the top-ranked locus across all uric acid GWAS studies, explaining roughly 3 to 4% of population-level variance (Köttgen et al., 2013)
• Dual transport function: GLUT9 also transports glucose and fructose, suggesting a molecular link between sugar metabolism and uric acid handling (Caulfield et al., 2008)
• Sex differences: The effect of SLC2A9 variants on uric acid is larger in women than in men, potentially contributing to the lower gout prevalence in premenopausal women (Dehghan et al., 2008)

ABCG2 (Q141K Variant)

ABCG2 is a urate transporter expressed in both the kidney and the intestine. The Q141K variant (rs2231142) is one of the strongest single genetic risk factors for gout:

• Functional impact: This missense mutation reduces the protein's ability to secrete uric acid into the gut lumen by roughly 50% (Woodward et al., 2009)
• Population prevalence: The Q141K variant is particularly common in East Asian populations, where it reaches allele frequencies of 25 to 30% (Nakayama et al., 2011)
• Gut excretion deficiency: Carriers effectively lose a major extra-renal excretion pathway, causing uric acid to accumulate even when kidney function is normal (Matsuo et al., 2009)
• Drug resistance implications: ABCG2 dysfunction may also reduce the effectiveness of certain urate-lowering therapies that rely on renal excretion (Ichida et al., 2012)

SLC22A12 (URAT1)

SLC22A12 encodes URAT1, the primary uric acid reabsorption transporter in the kidney:

• Gain-of-function variants increase reabsorption, raising serum uric acid and gout risk (Enomoto et al., 2002)
• Loss-of-function variants cause renal hypouricemia, a condition where uric acid levels drop below normal, virtually eliminating gout risk (Tin et al., 2019)
• Drug target: The gout medication lesinurad works by inhibiting URAT1, essentially mimicking the effect of protective genetic variants (Miner et al., 2016)

Other Contributing Loci

Beyond the big three, GWAS have identified additional loci that influence uric acid levels:

• SLC17A1: A renal phosphate and urate transporter on chromosome 6 (Kolz et al., 2009)
• SLC16A9: Involved in monocarboxylate transport, with indirect effects on urate handling (Köttgen et al., 2013)
• GCKR: A glucokinase regulatory protein gene linking glucose metabolism to purine breakdown and uric acid production (Kolz et al., 2009)
• ALDH16A1: Identified in Icelandic populations with a strong effect on gout risk independent of uric acid levels (Sulem et al., 2011)

Why Diet Affects People So Differently

The gene-diet interaction in gout is one of the clearest examples in all of medicine. A landmark 2018 study compared the relative contributions of diet and genetics to serum uric acid levels. Diet explained less than 1% of the variation in uric acid, while common genetic variants explained roughly 24% (Major et al., 2018). When rare variants and gene-gene interactions were included, the genetic contribution was even larger.

This does not mean diet is meaningless. For someone already near the crystallization threshold due to genetic predisposition, a purine-rich meal or a night of heavy drinking can be the trigger that pushes uric acid over the edge. Alcohol is particularly problematic for multiple reasons:

• Beer contains high levels of the purine guanosine, directly increasing uric acid production (Choi et al., 2004)
• All alcohol promotes dehydration and increases lactate production, which competes with uric acid for renal excretion (Faller & Fox, 1982)
• Fructose in mixers and sweetened beverages independently raises uric acid through purine nucleotide degradation (Choi & Curhan, 2008)

But for someone with favorable transporter genetics, the same meal may cause only a trivial bump in uric acid that the kidneys clear efficiently. This explains the common observation that many heavy drinkers never develop gout, while some people with modest alcohol intake suffer repeated flares.

Beyond Flares: Long-Term Health Consequences

Gout is not merely a painful nuisance. Chronically elevated uric acid is associated with serious systemic consequences:

• Kidney stones: Uric acid stones account for roughly 10% of all kidney stones, and the risk is strongly elevated in hyperuricemic individuals (Maalouf et al., 2004)
• Chronic kidney disease: Hyperuricemia accelerates renal function decline through crystal deposition and vascular effects (Johnson et al., 2013)
• Cardiovascular disease: A meta-analysis found that gout independently increases the risk of heart attack by roughly 60% and stroke by a similar margin (Clarson et al., 2015)
• Tophi and joint destruction: Untreated chronic gout leads to tophaceous deposits that erode bone and permanently damage joints (Dalbeth et al., 2018)

For individuals with high genetic risk, monitoring uric acid levels proactively, even before the first flare, could enable earlier intervention.

Gout Treatment and Pharmacogenomics

Genetic testing is already clinically relevant for gout treatment decisions:

• HLA-B*5801 screening: Allopurinol, the most commonly prescribed urate-lowering drug, can cause a severe and potentially fatal hypersensitivity reaction (Stevens-Johnson syndrome) in carriers of the HLA-B*5801 allele. This allele is present in roughly 6 to 8% of African Americans and 6 to 8% of Southeast Asian populations (Stamp et al., 2016). The American College of Rheumatology recommends screening before initiating allopurinol therapy (FitzGerald et al., 2020).
• Febuxostat: An alternative xanthine oxidase inhibitor for patients who cannot take allopurinol, though cardiovascular safety monitoring is advised (White et al., 2018)
• URAT1 inhibitors: Lesinurad and the newer compound verinurad target renal urate reabsorption; efficacy may vary depending on SLC22A12 genotype (Miner et al., 2016)

Understanding your specific genetic profile, whether the problem is overproduction, renal underexcretion, or gut underexcretion, can guide the most effective treatment strategy.

Key Takeaways

• Serum uric acid levels are approximately 65% heritable; genetics outweighs diet as the primary determinant
• SLC2A9, ABCG2, and SLC22A12 are the three most important genes controlling uric acid transport and gout risk
• The ABCG2 Q141K variant is especially prevalent in East Asian populations, helping explain regional differences in gout rates
• Diet explains less than 1% of uric acid variation at the population level, though it can trigger flares in genetically susceptible individuals
• Pharmacogenomic testing for HLA-B*5801 is recommended before starting allopurinol to prevent severe adverse reactions
• Chronic gout is linked to kidney disease, cardiovascular events, and permanent joint damage, making early intervention critical
• Genetic profiling can distinguish between overproduction and underexcretion subtypes, informing targeted therapy

Understand Your Gout Risk at the Genetic Level With GenomeInsight

Gout is not a lifestyle failure. It is a metabolic condition rooted in your DNA. GenomeInsight analyzes your genetic variants across the key urate transporter genes to give you a clear picture of your predisposition, along with actionable guidance for prevention and treatment. Upload your genetic data to get your personalized report, learn how our analysis works, or check out our pricing plans to get started today.

References

Caulfield, M. J., Munroe, P. B., O'Neill, D., Witkowska, K., Charchar, F. J., Doblado, M., ... & Dominiczak, A. F. (2008). SLC2A9 is a high-capacity urate transporter in humans. PLoS Medicine, 5(10), e197. https://doi.org/10.1371/journal.pmed.0050197

Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W., & Curhan, G. (2004). Purine-rich foods, dairy and protein intake, and the risk of gout in men. New England Journal of Medicine, 350(11), 1093-1103. https://doi.org/10.1056/NEJMoa035700

Choi, H. K., & Curhan, G. (2008). Soft drinks, fructose consumption, and the risk of gout in men: Prospective cohort study. BMJ, 336(7639), 309-312. https://doi.org/10.1136/bmj.39449.819271.BE

Clarson, L. E., Chandratre, P., Hider, S. L., Belcher, J., Heneghan, C., Roddy, E., & Mallen, C. D. (2015). Increased cardiovascular mortality associated with gout: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 22(3), 335-343. https://doi.org/10.1177/2047487313514895

Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2018). Gout. The Lancet, 388(10055), 2039-2052. https://doi.org/10.1016/S0140-6736(16)00346-9

Dehghan, A., Köttgen, A., Yang, Q., Hwang, S. J., Kao, W. L., Rivadeneira, F., ... & Fox, C. S. (2008). Association of three genetic loci with uric acid concentration and risk of gout. The Lancet, 372(9654), 1953-1961. https://doi.org/10.1016/S0140-6736(08)61343-4

Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S. H., ... & Endou, H. (2002). Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature, 417(6887), 447-452. https://doi.org/10.1038/nature742

Faller, J., & Fox, I. H. (1982). Ethanol-induced hyperuricemia: Evidence for increased urate production by activation of adenine nucleotide turnover. New England Journal of Medicine, 307(26), 1598-1602. https://doi.org/10.1056/NEJM198212233072602

FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., ... & Neogi, T. (2020). 2020 American College of Rheumatology guideline for management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180

Ichida, K., Matsuo, H., Takada, T., Nakayama, A., Murakami, K., Shimizu, T., ... & Shinomiya, N. (2012). Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Communications, 3, 764. https://doi.org/10.1038/ncomms1756

Johnson, R. J., Nakagawa, T., Jalal, D., Sánchez-Lozada, L. G., Kang, D. H., & Ritz, E. (2013). Uric acid and chronic kidney disease: Which is chasing which? Nephrology Dialysis Transplantation, 28(9), 2221-2228. https://doi.org/10.1093/ndt/gft029

Kolz, M., Johnson, T., Sanna, S., Teumer, A., Vitart, V., Perola, M., ... & Gieger, C. (2009). Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 5(6), e1000504. https://doi.org/10.1371/journal.pgen.1000504

Köttgen, A., Albrecht, E., Teumer, A., Vitart, V., Krumsiek, J., Hundertmark, C., ... & Gieger, C. (2013). Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nature Genetics, 45(2), 145-154. https://doi.org/10.1038/ng.2500

Maalouf, N. M., Cameron, M. A., Moe, O. W., Adams-Huet, B., & Sakhaee, K. (2004). Low urine pH: A novel feature of the metabolic syndrome. Clinical Journal of the American Society of Nephrology, 2(5), 883-888. https://doi.org/10.2215/CJN.00670207

Major, T. J., Topless, R. K., Dalbeth, N., & Merriman, T. R. (2018). Evaluation of the diet wide contribution to serum urate levels: Meta-analysis of population based cohorts. BMJ, 363, k3951. https://doi.org/10.1136/bmj.k3951

Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440(7081), 237-241. https://doi.org/10.1038/nature04516

Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Nakayama, A., Ikebuchi, Y., ... & Shinomiya, N. (2009). Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. Science Translational Medicine, 1(5), 5ra11. https://doi.org/10.1126/scitranslmed.3000237

Miner, J. N., Tan, P. K., Hyndman, D., Liu, S., Ponton, C., Simber, J., ... & Lesinurad Study Group. (2016). Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Research & Therapy, 18, 214. https://doi.org/10.1186/s13075-016-1107-x

Nakayama, A., Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Ikebuchi, Y., ... & Shinomiya, N. (2011). ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. Nucleosides, Nucleotides and Nucleic Acids, 30(12), 1091-1097. https://doi.org/10.1080/15257770.2011.633953

Oda, M., Satta, Y., Takenaka, O., & Takahata, N. (2002). Loss of urate oxidase activity in hominoids and its evolutionary implications. Molecular Biology and Evolution, 19(5), 640-653. https://doi.org/10.1093/oxfordjournals.molbev.a004123

Sorensen, L. B. (1965). Role of the intestinal tract in the elimination of uric acid. Arthritis & Rheumatism, 8(5), 694-706. https://doi.org/10.1002/art.1780080429

Stamp, L. K., Day, R. O., & Yun, J. (2016). Allopurinol hypersensitivity: Investigating the cause and minimizing the risk. Nature Reviews Rheumatology, 12(4), 235-242. https://doi.org/10.1038/nrrheum.2015.132

Sulem, P., Gudbjartsson, D. F., Walters, G. B., Helgadottir, H. T., Helgason, A., Gudjonsson, S. A., ... & Stefansson, K. (2011). Identification of low-frequency variants associated with gout and serum uric acid levels. Nature Genetics, 43(11), 1127-1130. https://doi.org/10.1038/ng.972

Tin, A., Marten, J., Kuhns, V. L. H., Li, Y., Wuttke, M., Kirsten, H., ... & Köttgen, A. (2019). Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nature Genetics, 51(10), 1459-1474. https://doi.org/10.1038/s41588-019-0504-x

Vitart, V., Rudan, I., Hayward, C., Gray, N. K., Floyd, J., Palmer, C. N., ... & Wright, A. F. (2008). SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 40(4), 437-442. https://doi.org/10.1038/ng.106

White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., ... & CARES Investigators. (2018). Cardiovascular safety of febuxostat or allopurinol in patients with gout. New England Journal of Medicine, 378(13), 1200-1210. https://doi.org/10.1056/NEJMoa1710895

Woodward, O. M., Köttgen, A., Coresh, J., Boerwinkle, E., Guggino, W. B., & Köttgen, M. (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proceedings of the National Academy of Sciences, 106(25), 10338-10342. https://doi.org/10.1073/pnas.0901249106

---

Related Reading

• type 2 diabetes genetics
• obesity genetics
• heart disease genetics
• polygenic risk scores